Atara Biotherapeutics (ATRA) Return on Capital Employed (2014 - 2026)
Atara Biotherapeutics (ATRA) posted Return on Capital Employed of 43.6% for Q1 2026, down 112.5% on a QoQ basis from 348.89% in Q4 2025, and down 806.0% year-over-year from 6.18% in Q1 2025.
Atara Biotherapeutics (ATRA) Return on Capital Employed (2014 - 2026) Analysis & Trends
Atara Biotherapeutics' Return on Capital Employed history runs 13 years deep, the most recent figure standing at 43.6% for Q1 2026.
- Quarterly Return on Capital Employed fell 806.0% year-over-year to 43.6% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 43.6% (down 806.0% YoY) and the FY2025 annual result came in at 72.09%, up 313179.0% from the prior year.
- Return on Capital Employed was 43.6% for Q1 2026 at Atara Biotherapeutics, down from 348.89% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 2561.91% in Q2 2024 and bottomed at 790.4% in Q4 2023.
- A 5-year average of 257.59% and a median of 43.6% in 2026 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed surged 271543 bps — and 2025, when it plunged 253888 bps.
- Atara Biotherapeutics' Return on Capital Employed stood at 95.59% in 2022, then slumped by 727 bps to 790.4% in 2023, then jumped by 222 bps to 962.15% in 2024, then slumped by 64 bps to 348.89% in 2025, then slumped by 112 bps to 43.6% in 2026.
- Business Quant data shows ATRA's Return on Capital Employed at 43.6% in Q1 2026, 348.89% in Q4 2025, and 169.42% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | Atara Biotherapeutics | 110.04 Mn | 101.68 Mn | 392,000.00 | -43.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.60% |
| Dec 31, 2025 | 348.89% |
| Sep 30, 2025 | 169.42% |
| Jun 30, 2025 | 23.03% |
| Mar 31, 2025 | -35.54% |
| Dec 31, 2024 | 962.15% |
| Sep 30, 2024 | 504.91% |
| Jun 30, 2024 | 2,561.91% |
| Mar 31, 2024 | 1,517.68% |
| Dec 31, 2023 | -790.40% |
| Sep 30, 2023 | -210.49% |
| Jun 30, 2023 | -153.52% |
| Mar 31, 2023 | -98.50% |
| Dec 31, 2022 | -95.59% |
| Sep 30, 2022 | -90.42% |
| Jun 30, 2022 | -85.06% |
| Mar 31, 2022 | -105.83% |
| Dec 31, 2021 | -96.38% |
| Sep 30, 2021 | -89.53% |
| Jun 30, 2021 | -78.80% |